1. Introduction {#sec1}
===============

The link between nutrition and the risk of developing Alzheimer\'s disease (AD) has been recognized for several decades. Specific dietary patterns have been associated with increased risk of developing AD, whereas others are linked to protection. Dietary patterns such as the Mediterranean diet that is characterized by high intakes of legumes, fruits, fish, unsaturated fats, and high in antioxidants offer protection [@bib1]. Conversely, diets high in saturated fats, high trans-fat, and low antioxidants levels have been linked to an increased risk for developing AD [@bib2]. In addition, diet-related disorders such as obesity, hypertension, hypercholesterolemia, and diabetes have consistently been shown to be associated with AD [@bib3], [@bib4], [@bib5].

Since understanding the pivotal importance of B-vitamins for neuronal functioning and cognition, at the beginning of the 20th century [@bib6], [@bib7], [@bib8], several nutrients, including antioxidants, choline, and omega-3 fatty acids, have been suggested to influence cerebral functioning (reviewed in Bourre [@bib9] and in Smith and Blumenthal [@bib10]). It is no surprise, therefore, that these nutrients have been postulated to play roles in the pathophysiological processes in AD. For example, antioxidants reduce reactive oxygen species--induced damage and stabilize membranes; the fatty acid docosahexaenoic acid (DHA) affects abnormal membrane--located protein processing (amyloid-b, tau); and DHA, choline, and uridine modulate neuronal membrane formation (reviewed in van Wijk et al. [@bib11]). Neuronal membrane function has been shown to be dependent on its phospholipid composition, and alterations could lead to membrane instability and synaptic loss and, in that way, contribute to AD pathology [@bib12]. Recent evidence suggests that a multinutrient intervention which enhances phospholipid formation comprising DHA, eicosapentaenoic acid (EPA), uridine monophosphate, choline, folate, vitamin B~6~, vitamin B~12~, vitamin C, vitamin E, selenium, and phospholipids modulated functional connectivity measures (assessed by electroencephalography) in AD, indicative of preserved synaptic function [@bib13], [@bib14]. These data suggest that adequate supply of specific nutrients may preserve synaptic function, prevent neurodegeneration, and eventually neuronal loss, while previous work showed that people with AD have lower systemic availability of several nutrients that may limit optimal brain function [@bib15]. Publications on brain nutrients in AD compared with non-AD suggest differences in brain nutrient levels as well, but the available evidence is not fully consistent and systematic reviews are lacking.

The main objective of this review was to evaluate the presence of differences in brain nutrient levels between AD patients and cognitively intact elderly controls. In addition, systemic availability of nonvitamin nutrients will be evaluated to extend our earlier work on plasma vitamin availability in AD [@bib15]. All relevant literature studies published after 1980 in Medline, Embase, and the Cochrane Central Register of Controlled Trials were reviewed using the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines [@bib16].

2. Methods {#sec2}
==========

2.1. Search strategy and selection criteria {#sec2.1}
-------------------------------------------

Relevant literature published from 1980 to June 26, 2015 was systematically screened in the Cochrane Central Register of Controlled Trials, Medline, and Embase electronic databases according to PRISMA guidelines [@bib16] using the following search terms in the title, abstract, or descriptors: (Alzheimer\* and \[humans or patients or inpatients or outpatients or persons or volunteers or participants or subjects\] and \[nutrition or nutritional or nutrient or nutrients or micronutrient or micronutrients or diet or diets or dietary or vitamin or vitamins or mineral or minerals or trace-element or trace-elements or fatty-acid or fatty-acids or PUFA or PUFAs or ^1^H-MRS (proton magnetic resonance spectroscopy) or MRS or MR spectroscopy\]).

The search in the Cochrane Central Register of Controlled Trials, Embase, and Medline resulted in 11,389 published studies that were imported into Endnote (see [Fig. 1](#fig1){ref-type="fig"} for the breakdown of publication selection). Duplicate references were automatically removed, followed by manual examination, which retrieved another 173 duplicate references. Conference abstracts (1474), non-English publications (640), publications with nonhuman data (1719), and Reviews, Editorials, Letters, Notes, Short Surveys, Comments, Case Reports (2180) were all removed from the database. The title and abstract of the remaining 5203 publications were evaluated according to predefined exclusion and inclusion criteria.Fig. 1Breakdown of the retrieved publications leading to the selection of the 116 publications suitable for meta-analysis. Abbreviation: AD, Alzheimer\'s disease.

Included were those papers that might contain plasma or brain nutrient levels of AD patients, even if not explicitly mentioned in the abstract. Five hundred twenty-eight of the retrieved publications were identified as being of potential relevance. The full text of these publications was analyzed according to the following inclusion criteria: contained AD patient population according to the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer\'s Disease and Related Disorders Association criteria [@bib17] and/or the Diagnostic and Statistical Manual for Mental Disorders [@bib18] criteria for AD and mentioned the use of a cognitively intact elderly control group, mean and standard deviation, plasma or serum or brain or cerebrospinal fluid (CSF) levels of nutrients, number of AD patients and controls, and mean age or age range of AD and control groups.

Analysis of the retrieved documents revealed that some of these publications concerned data that were derived from the same population of patients. In this case, the publication with the most complete set of data was included. The following studies were excluded: those concerning other cognitive disorders (e.g., mild cognitive impairment, vascular dementia, frontotemporal dementia, or psychogeriatric disease); those that included subjects using vitamin supplements; and those not written in English. Botanicals, resveratrol, curcumin, beta-carotene, and heavy metals (aluminum and mercury) were also excluded because these are not considered micronutrients.

For circulatory nutrient status plasma, serum and erythrocyte levels (in order of preference) were eligible for inclusion. Exception was made for circulatory choline status where, in the context of AD, plasma phosphatidylcholine (PC) level is considered a better choline status indicator than free or total choline levels [@bib19]. For brain nutrient status, both the tissue and CSF levels (in order of preference) were eligible for inclusion. Brain choline status was evaluated by including publications reporting choline levels based on ^1^H-MRS. Publications reporting relative or absolute choline levels were included, whereas publications reporting choline as a ratio over creatine were excluded for the meta-analysis. For publications reporting tissue/^1^H-MRS nutrient levels in different brain regions, only one brain region per nutrient per study was selected to perform statistical analysis. Selection criteria for brain regions follow the order: hippocampus, dentate gyrus of the hippocampus, parahippocampal cortex, temporal lobe/cortex and subdivisions, piriform cortex, frontal lobe/cortex and subdivisions, prefrontal cortex, parietal lobe/cortex and subdivisions, whole brain, and pituitary gland. Furthermore, levels of brain DHA were reported in different phospholipid fractions for which the following order of preference was used: PC, phosphatidylethanolamine, choline glycerophospholipid, phosphatidylserine, phosphatidylinositol, diacylphosphatidylcholine, choline phosphoglyceride.

2.2. Statistical analysis {#sec2.2}
-------------------------

All reported comparisons of plasma/serum and brain/CSF nutrient levels in AD patients and controls were integrated and summarized into a final result per nutrient, using meta-analysis (regression) methods [@bib20], according to the PRISMA statement [@bib16]. For each nutrient, we extracted from the articles the mean and standard deviation of plasma/serum or brain/CSF levels in AD patients and controls as well as the number of subjects and the average age per group. Comparison across publications did not require conversion to the same unit because our analysis was based on the difference between groups, that is, not on the absolute value. These data were analyzed using the random-effects meta-analysis model [@bib20] fitted by restricted maximum likelihood using the program metareg of Stata (StataCorp. 2001. Statistical Software: Release 12.1; College Station, TX, USA). For this analysis, a minimum of four studies is generally required [@bib21], [@bib22]. No meta-analysis was performed when less than four publications were identified; however, a mention is made in Section [3](#sec3){ref-type="sec"} indicating the number of publications found. No mention is made for those nutrients for which no publications were identified for both circulatory and central levels.Fig. 2Results of meta-analyses for circulatory nutrient levels in AD patients and cognitively intact elderly controls. (A) DHA levels are significantly lower in AD patients (*P* \< .05) and approximately 75% of the absolute amount in the control subjects; (B) EPA levels are significantly lower in AD patients (*P* \< .05) and approximately 89% of the absolute amount in the control subjects; (C) choline (as PC) levels are significantly lower in AD patients (*P* \< .05) and approximately 88% of the absolute amount in the control subjects; (D) vitamin B~6~ levels are not significantly different in AD patients (*P* = .3634); (E) Selenium levels are significantly lower in AD patients (*P* \< .05) and approximately 93% of the absolute amount in the control subjects. Abbreviations: AD, Alzheimer\'s disease; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LCL, lower confidence limit; PC, plasma phosphatidylcholine; REML, restricted maximum likelihood; SD, standard deviation; UCL, upper confidence limit.

Because it is known that the plasma/serum and brain/CSF levels of several nutrients can vary with age [@bib23], meta-analyses were conducted with and without a correction by meta-regression for differences in mean age between AD patients and controls. The final result for a given nutrient was based on the results of the meta-analysis with this centralized age adjustment.

3. Results {#sec3}
==========

The objectives of this study were to assess whether circulatory (see Section [3.1](#sec3.1){ref-type="sec"}) and brain (see Section [3.2](#sec3.2){ref-type="sec"}) nutrient levels differ between AD patients and cognitively intact elderly controls. The current investigation resulted in the identification of 116 publications ([Fig. 1](#fig1){ref-type="fig"}) that met all inclusion criteria, some of which described plasma and/or brain levels of multiple nutrients. Meta-analyses were performed with a correction by meta-regression for centralized age differences between AD patients and controls. [Table 1](#tbl1){ref-type="table"} provides a summary of the included publications, listing for each nutrient the number of publications reporting significant lower or higher nutrient levels and the number of publications showing no difference in nutrient levels between AD patients and controls.Table 1Summary of the included publications for the meta-analysisCompartmentNutrientTotal number of publicationsTotal number of AD patients/average age (years)Total number of control subjects/average age (years)Studies reporting significantly lower levels in AD patients than in controlsStudies reporting no significant differences between AD patients and controlsStudies reporting significantly higher levels in AD patients than in controlsCirculationDHA13488/781245/72Six studies [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29]Seven studies [@bib30], [@bib31], [@bib32], [@bib33], [@bib34], [@bib35], [@bib36]EPA13488/781245/72Six studies [@bib24], [@bib25], [@bib26], [@bib28], [@bib32], [@bib35]Seven studies [@bib27], [@bib29], [@bib30], [@bib31], [@bib33], [@bib34], [@bib36]Choline (as PC)487/7676/73Two studies [@bib37], [@bib38]Two studies [@bib24], [@bib39]Vitamin B~6~6192/76199/75Two studies [@bib40], [@bib41]Four studies [@bib34], [@bib42], [@bib43], [@bib44]Selenium17660/77536/72Seven studies [@bib34], [@bib45], [@bib46], [@bib47], [@bib48], [@bib49], [@bib50]Eight studies [@bib51], [@bib52], [@bib53], [@bib54], [@bib55], [@bib56], [@bib57], [@bib58]Two studies [@bib59], [@bib60]BrainDHA12237/77220/75Four studies [@bib61], [@bib62], [@bib63], [@bib64]Eight studies [@bib65], [@bib66], [@bib67], [@bib68], [@bib69], [@bib70], [@bib71], [@bib72]Choline (^1^H-MRS)31828/73791/70Four studies [@bib73], [@bib74], [@bib75], [@bib76]Twenty-seven studies [@bib77], [@bib78], [@bib79], [@bib80], [@bib81], [@bib82], [@bib83], [@bib84], [@bib85], [@bib86], [@bib87], [@bib88], [@bib89], [@bib90], [@bib91], [@bib92], [@bib93], [@bib94], [@bib95], [@bib96], [@bib97], [@bib98], [@bib99], [@bib100], [@bib101], [@bib102], [@bib103]Folate9307/73538/65Four studies [@bib104], [@bib105], [@bib106], [@bib107]Five studies [@bib108], [@bib109], [@bib110], [@bib111], [@bib112]Vitamin B~12~492/70208/69Two studies [@bib110], [@bib113]Two studies [@bib114], [@bib115]Vitamin C5102/7479/70Four studies [@bib41], [@bib116], [@bib117], [@bib118]One study [@bib119]Vitamin E5127/73100/70Three studies [@bib116], [@bib120], [@bib121]Two studies [@bib117], [@bib118]Selenium13487/76353/76Three studies [@bib122], [@bib123], [@bib124]Ten studies [@bib46], [@bib58], [@bib125], [@bib126], [@bib127], [@bib128], [@bib129], [@bib127], [@bib128], [@bib129], [@bib130], [@bib131], [@bib132]Zinc16496/73306/71Five studies [@bib122], [@bib123], [@bib133], [@bib134], [@bib135]Ten studies [@bib46], [@bib125], [@bib127], [@bib128], [@bib130], [@bib132], [@bib136], [@bib137], [@bib138], [@bib139]One study [@bib126][^1]

3.1. Circulatory nutrient meta-analysis {#sec3.1}
---------------------------------------

Thirty-seven publications reporting on circulatory nutrient levels in patients with AD and cognitively intact elderly controls were identified. Meta-analyses were possible for circulatory DHA (13 studies), EPA (13 studies), PC (4 studies), vitamin B~6~ (6 studies), and selenium (17 studies) ([Fig. 2](#fig2){ref-type="fig"}A--E and [Table 1](#tbl1){ref-type="table"}) because the literature search had yielded four or more publications for each of these nutrients. In addition, the systematic literature search yielded recent meta-analyses on circulatory iron [@bib140], magnesium [@bib141], and zinc [@bib142]. Unfortunately, insufficient number of publications were retrieved reporting on circulatory manganese (two studies [@bib51], [@bib55]). Significantly lower levels of circulatory DHA ([Fig. 2](#fig2){ref-type="fig"}A, *P* \< .004), EPA ([Fig. 2](#fig2){ref-type="fig"}B, *P* \< .03), PC levels ([Fig. 2](#fig2){ref-type="fig"}C, *P* \< .001), and selenium ([Fig. 2](#fig2){ref-type="fig"}E, *P* \< .05) were found in AD patients compared with cognitively intact elderly controls. No significant differences were observed in circulatory vitamin B~6~ levels ([Fig. 2](#fig2){ref-type="fig"}D, *P* = .3634). For completeness, the results of meta-analyses without centralized age correction are also provided in the figures.

3.2. Brain nutrient meta-analysis {#sec3.2}
---------------------------------

Eighty-two publications reporting on brain nutrient levels in patients with AD and cognitively intact elderly controls were identified. Meta-analyses were possible for brain DHA (12 studies), brain choline-containing lipids (^1^H-MRS, 31 studies), CSF folate (9 studies), CSF vitamin B~12~ (4 studies), CSF vitamin C (5 studies), CSF vitamin E (5 studies), brain selenium (13 studies), and brain zinc (16 studies) ([Fig. 3](#fig3){ref-type="fig"}A--H and [Table 1](#tbl1){ref-type="table"}). Unfortunately, the systematic literature search did not yield sufficient number of publications reporting on brain EPA (three studies [@bib61], [@bib66], [@bib69]), vitamin A (zero studies), vitamin B~1~ (zero studies), vitamin B~6~ (zero studies), vitamin D (one study [@bib144]), calcium (two studies [@bib59], [@bib134]), magnesium (two studies, see Veronese et al. [@bib141]), and manganese (three studies [@bib123], [@bib135], [@bib137]).Fig. 3Meta-analyses results for brain nutrient levels in AD patients and cognitively intact elderly controls. (A) DHA levels are significantly lower in AD patients (*P* \< .003) and approximately 85% of the absolute amount in the control subjects; (B) choline-containing lipids (^1^H-MRS) levels are significantly lower in AD patients (*P* \< .05) and approximately 95% of the absolute amount in the control subjects; (C) folate levels are significantly lower in AD patients (*P* \< .001) and approximately 89% of the absolute amount in the control subjects; (D) vitamin B~12~ levels are significantly lower in AD patients (*P* \< .012) and approximately 78% of the absolute amount in the control subjects; (E) vitamin C levels between AD patients and cognitively intact elderly controls were significant (*P* \< .01) and approximately 80% of the absolute amount in the control subjects; (F) vitamin E levels are significantly lower in AD patients (*P* \< .001) and approximately 81% of the absolute amount in the control subjects; (G) selenium levels are not significant different in AD patients (*P* = .249); (H) zinc levels are not significantly different in AD patients (*P* = .507). Abbreviations: AD, Alzheimer\'s disease; DHA, docosahexaenoic acid; LCL, lower confidence limit; REML, restricted maximum likelihood; SD, standard deviation; UCL, upper confidence limit.

Significantly lower levels of brain DHA ([Fig. 3](#fig3){ref-type="fig"}A, *P* \< .003), brain choline-containing lipids ([Fig. 3](#fig3){ref-type="fig"}B, *P* \< .0011), CSF folate ([Fig. 3](#fig3){ref-type="fig"}C, *P* \< .001), CSF vitamin B~12~ ([Fig. 3](#fig3){ref-type="fig"}D, *P* = .012), CSF vitamin C ([Fig. 3](#fig3){ref-type="fig"}E, *P* \< .001), and CSF vitamin E ([Fig. 3](#fig3){ref-type="fig"}F, *P* \< .001) were found in AD patients compared with cognitively intact elderly controls. No significant differences were observed for brain selenium ([Fig. 3](#fig3){ref-type="fig"}G, *P* = .249) and brain zinc ([Fig. 3](#fig3){ref-type="fig"}H, *P* = .507) levels. For completeness, the results of meta-analyses without centralized age correction are also provided in the figures.

3.3. Summary of the overall nutrient status in patients with AD {#sec3.3}
---------------------------------------------------------------

[Figure 4](#fig4){ref-type="fig"} shows the collective results of this meta-analysis combined with previous work from our group, as well as three recent meta-analyses on mineral status in AD. The levels of the respective nutrients are expressed as a percentage of cognitively healthy elderly. Significantly lower blood levels of DHA, EPA, choline, and selenium (75%, 89%, 88%, and 93% of control levels, respectively) and significantly lower brain levels of DHA, choline, folate, vitamin B~12~, vitamin C, vitamin E, and copper (85%, 95%, 89%, 78%, 80%, 81%, and 86% of control levels, respectively) were found in patients with AD.Fig. 4Brain and circulatory nutrient levels in AD versus cognitively intact elderly controls. Summary of the circulatory (top panel) and brain (lower panel) nutrient status of AD patients (including \[1\] current meta-analyses; \[2\] previous meta-analyses results from Lopes da Silva et al. [@bib15]; \[3\] recent meta-analyses for circulatory and brain iron Tao et al. [@bib140]; \[4\] recent meta-analysis for circulatory magnesium Veronese et al. [@bib141]; \[5\] recent meta-analysis for circulatory zinc Ventriglia et al. [@bib142]; \[6\] recent meta-analysis for brain copper Schrag et al. [@bib143] status; respectively presented as numbers above the bars). Data are represented as the weighted average percentage of controls ± standard error of the mean. \*Indicates statistical significance; \# indicates trend for significance; ns indicates nonsignificance; nd indicates not determined with meta-analysis. Abbreviation: AD, Alzheimer\'s disease.

4. Discussion {#sec4}
=============

To our knowledge, this is the first systematic comparison of brain nutrient levels in AD patients to those in cognitively intact elderly controls. Several studies suggest lower brain nutrient levels in AD, but conclusive data that their levels are different in AD patients compared with controls have thus far been lacking. Integrating the results of all published studies in the current meta-analysis provides an unequivocal answer to the research objective for brain DHA, choline, folate, vitamin B~12~, vitamin C, and vitamin E. In addition, meta-analyses showing lower levels of circulatory DHA, EPA, PC, and selenium complement prior work on lower circulatory vitamin status in AD patients [@bib15]. The results as a whole disclose directionally aligned results between brain and circulatory nutrient status, that is, nutrients found to be lower in the circulation also show lower status in the brain of AD patients. The magnitude, 5%--25% lower concentrations in AD, of the differences was found to be comparable between circulation and brain nutrient status. The factors that could contribute to the lower circulatory (Section [4.1](#sec4.1){ref-type="sec"}) and brain (Section [4.2](#sec4.2){ref-type="sec"}) nutrient levels are discussed in the following section, along with the potential implications (Section [4.4](#sec4.4){ref-type="sec"}) for people with AD.

4.1. Factors contributing to lower circulatory nutrient levels {#sec4.1}
--------------------------------------------------------------

Collectively, the current and previous meta-analyses show lower circulatory status for specific nutrients (respectively, DHA + EPA + PC + selenium and vitamins A, B~12~, C, E, folate). A logical origin for these lower levels may be lower intake, which could be explained from an epidemiological point of view. Epidemiological studies suggest that better adherence to healthy diets, for example, a Mediterranean diet, is associated with reduced risk of developing AD (see, for review, van de Rest et al. [@bib145]) and high adherence to a Western dietary pattern is associated with elevated AD risk [@bib146]. High adherence to the Mediterranean diet, compared with the Western dietary pattern, is associated with higher intakes of omega-3 PUFAs, B-vitamins and antioxidants, and specific nutrient biomarker patterns [@bib147], [@bib148]. In addition, lower circulatory nutrient levels might also be explained by lower food intake associated with malnutrition and weight loss (indicative for protein/energy malnutrition) which are common problems in AD, occurring especially at the moderate-to-severe stages of the disease [@bib149], [@bib150], [@bib151]. Although eating difficulties are also associated with mild-to-moderate and early stages of AD [@bib152], signs of protein/energy malnourishment are less prevalent, with 2.5%--3% of the mild-to-moderate patients being malnourished and ∼18% at risk of malnutrition [@bib153] while, in newly diagnosed AD, prevalence of protein/energy malnutrition was 0% and 14.1% was at risk of malnutrition [@bib154]. The lower nutrient levels in AD do not necessarily originate from protein/energy malnourishment as demonstrated in previous meta-analyses showing lower plasma vitamin levels in AD patients without signs of malnutrition [@bib15]. Other factors associated with AD may also influence circulatory nutrient levels, such as nutrient liberation from food, nutrient uptake from the gut, efficiency with which nutrients are transported over physiological barriers, and the major controlling influence of the liver. A growing number of publications underscore the impact of AD on nutrient-related pathways.

First, apolipoprotein E (*APOE*) ε4 allele is one of the strongest genetic risk factor for AD. apoE plays a crucial role in the transport and homeostasis of lipids in the bloodstream, where it participates in the delivery and clearance of serum triglycerides, phospholipids, and cholesterol [@bib155], [@bib156] and as such it is involved in the transport of DHA in the circulation [@bib157]. In addition, apoE has been indicated in transport and regulation of lipid-soluble vitamins, for example, vitamins A, E, and K [@bib158], [@bib159], [@bib160]. A recent meta-analysis shows lower circulatory apoE levels in AD patients compared with healthy controls [@bib161]. Lower apoE levels could compromise the availability of lipids and lipid-soluble vitamins and thereby contributing to the lower DHA and EPA levels observed in the current meta-analysis and the lower vitamin A and E in previous work from our group [@bib15]. Unfortunately, most of the publications included in this meta-analysis lacked *APOE*-status data thereby preventing the possibility to perform meta-analyses to study the impact of *APOE* status on nutrient-level differences.

Second, several gene polymorphisms influencing the risk of AD are found for genes-encoding enzymes involved in the metabolism and transport of nutrients. Polymorphisms in the genes encoding for *MTHFR* (methylenetetrahydrofolate reductase) [@bib162] and *MTHFD1L* (methylenetetrahydrofolate dehydrogenase \[NADP^+^ dependent\] 1--like protein) [@bib163] negatively influence key enzymes involved in the metabolism of homocysteine to form methionine. Similarly, polymorphisms in the gene encoding for an important carrier of vitamin B~12~ in the circulation (transcobalamin II) are suggested to have a protective role against AD and are found to be occurring less often in patients with AD [@bib164]. These polymorphisms provide a genetic basis for the long observed elevated homocysteine levels in AD indicative for compromised one-carbon metabolism and suggestive for higher requirements for vitamin B~12~ and folate.

Third, studies using metabolomics approaches indicate that abnormalities in metabolic pathways accumulate with disease progression. The affected pathways range from fatty acid metabolism, one-carbon metabolism, energy metabolism, Krebs cycle, mitochondrial function, nucleic acid metabolism, but also neurotransmitter and amino acid metabolism, and lipid biosynthesis [@bib165], [@bib166]. In line with these findings, patients with AD also show altered phospholipid metabolism [@bib33], [@bib167], [@bib168]. As most of these metabolic pathways use nutrients, the aforementioned findings indirectly confirm the lower nutrient status observed in the current and former meta-analyses of circulatory nutrient levels.

Finally, reduced functionality of specific liver-residing enzymes involved in nutrient conversion, for example, compromised formation of DHA from α-linolenic acid [@bib61] or the reduced capacity to form PC from phosphatidylethanolamine [@bib27]. As phosphatidylethanolamine is rich in DHA, a compromised conversion to PC reduces the total DHA content in blood phospholipids. Together with the reduced capacity to synthesize DHA from *α*-linolenic acid, these data provide a mechanistic basis that could contribute to the lower DHA levels in patients with AD as observed in this meta-analysis.

The aforementioned findings suggest that differences in circulatory nutrient levels in AD are not only dependent on dietary intake but may be affected by several AD-associated differences in genetic, metabolic, and transport mechanisms related to nutrient handling/metabolism. As the brain has very limited capacity for de novo nutrient synthesis, it depends on the circulation to maintain an adequate nutrient availability [@bib9], [@bib169]. Taken together, these AD-associated differences in the periphery may impose the brains of patients with AD with an inadequate nutrient supply.

4.2. Factors contributing to lower brain nutrient levels {#sec4.2}
--------------------------------------------------------

In the brain, multiple, separate carrier systems at the blood-brain barrier and at the blood-CSF barrier mediate the transport of fatty acids, vitamins, minerals, and nucleosides from the circulation into the CSF and extracellular space of the brain [@bib170], [@bib171], [@bib172], [@bib173], [@bib174], [@bib175]. Indeed, the current meta-analysis results suggest that brain nutrient status is reflecting the status in the periphery. Yet, comparable to the periphery where dietary intake is not the only factor determining nutrient levels, in the brain, other factors than uptake from the circulation also can influence nutrient levels. In fact, several of the peripheral AD-associated differences in genetic, metabolic, and transport mechanisms related to nutrient handling/metabolism are also observed in the brain. First, apoE levels are found to be reduced in CSF of patients with AD [@bib176], thereby probably impacting lipid and lipid-soluble vitamin availability to neurons [@bib155]. Second, a polymorphism within the gene-encoding transcobalamin II is associated with lower CSF transcobalamin concentrations in patients with AD, which could explain the lower vitamin B~12~ status resulting from this meta-analysis. Third, metabolomics studies in CSF of AD patients show alterations in metabolic pathways [@bib165], [@bib177] partly overlapping with the altered pathways observed in the periphery, including altered phospholipid metabolism which has been observed from the mid 1980s [@bib178]. Finally, although the brain cannot synthesize DHA, a recent publication observed that lower CSF Aβ42 levels were associated with lower transport of DHA to CSF, suggesting that the presence of amyloid pathology may limit the delivery of DHA to the brain in AD [@bib179].

In addition, brains of people with AD are vulnerable to loss of membrane PC as a result of free choline generation for the synthesis of acetylcholine [@bib180]. This process of choline liberation exclusively operates at the synapse [@bib181] and when excessive destruction of membrane PC might lead to changes in membrane composition and loss in total membrane surface [@bib180], [@bib182] and are in line with the aforementioned alterations in brain phospholipid metabolism. Prolonged duration of these alterations is likely to impact neuronal function, first at the synaptic level and later spreading to the neuronal cell body [@bib180]. Indeed, AD is associated with loss of synaptic function and lower synapse numbers [@bib183], [@bib184], and these changes are the major correlates of cognitive impairment observed in AD [@bib185].

4.3. Strengths and limitations {#sec4.3}
------------------------------

The strength and uniqueness of the current meta-analysis approach is that it allows demonstration of lower levels of a variety of nutrients both in the brain and in the circulation of patients with AD compared with cognitively intact elderly. Further strengths are the inclusion of case-control studies only and the correction for age differences as a possible confounding factor. Several limitations that could have influenced the overall result of the present meta-analysis warrant mention. First, habitual dietary intake information of the AD and control groups is not provided in all publications. However, our previous meta-analysis showed that differences in plasma nutrient levels were consistent albeit analyzing only studies with no difference in measures of protein/energy malnourishment between AD patients and controls [@bib15]. In all cases, we excluded publications that involved subjects using vitamin supplements. Between-study heterogeneity was also observed which can be attributed to variation in sample size, gender, and the ethnic backgrounds of the participants. Another source of heterogeneity would be the stage of disease. However, most of the publications included for the current meta-analyses studied AD populations in the early and mild-to-moderate phase of AD limiting the impact of malnutrition induced by eating difficulties [@bib152], [@bib153], [@bib154]. Third, there is limited number of eligible studies for circulatory vitamin B~6~ and choline and for brain vitamins B~12~, C, and E levels which warrant caution to interpretation of the meta-analyses results. Fourth, although the current meta-analyses offer insight in the status for a number of nutrients, there is still insufficient information available for a range of vitamins such as vitamin D, B-vitamins, and for minerals. This is more apparent for nutrient status in the brain compared with the circulation. Fifth, very few studies simultaneously measured circulatory and central nutrient status thereby limiting the possibility to detect parallels or differences between the two compartments. Such studies would advance the understanding of nutritional needs of the brain in AD. Finally, most of the included studies do not offer the possibility to study the temporal relationship between AD-pathophysiology and nutrient status, to determine when in the disease spectrum the lower levels begin to manifest.

4.4. Interpretation {#sec4.4}
-------------------

Collectively, this body of evidence suggests that AD is associated with specific compromised nutrient availability. Although dietary intake is an important factor influencing nutrient levels, AD is also associated with several differences in genetic, metabolic, and transport mechanisms related to nutrient handling/metabolism that could contribute to the lower nutrient status. The consequences of these differences are unknown but possibly have a negative influence on disease progression. The importance of adequate nutrient levels is illustrated briefly by highlighting a number of mechanisms associated with the development of AD neuropathology and involving nutrients.

First, adequate nutrient levels as a necessity for the synthesis of phospholipids that make up synaptic membranes (reviewed in van Wijk et al. [@bib11]) are emphasized by the notion that disrupted phospholipid homeostasis in AD is recognized and confirmed in many studies since the 80s both in the brain and in the circulation [@bib33], [@bib64], [@bib69], [@bib70], [@bib168], [@bib178], [@bib180], [@bib186], [@bib187], [@bib188], [@bib189], [@bib190], [@bib191], [@bib192]. Disruption of phospholipid homeostasis and the loss of synaptic function and synapse numbers [@bib184], [@bib185], [@bib193] appear to go hand-in-hand [@bib194], [@bib195] as co-occurring hallmarks of AD and disease progression. The declining synapse numbers in AD suggest that patients may have a higher need for forming new synapses which may increase the need for adequate phospholipid synthesis.

Second, nutrients also serve crucial roles in epigenetic mechanisms via DNA methylation, histone, and microRNAs modifications (reviewed in Athanasopoulos et al. [@bib196]). Especially, the B-vitamins (B~12~, folate, and B~6~) are used as cofactors in the methionine cycle (or one-carbon cycle metabolism) and are critical for the regeneration of S-adenosylmethionine from homocysteine. Lower generation of S-adenosylmethionine, which is a methyl donor, could lead to lower DNA methylation capacity, resulting in overexpression of genes involved in AD pathology [@bib197]. Other nutrients, such as vitamins A, C, and E, through their antioxidant properties can affect the proteins involved in the transmethylation reactions necessary for the methylation/demethylation of DNA [@bib196]. In addition, lower antioxidant capacity may also lead to modifications of histone deacetylases thereby limiting deacetylase activity [@bib198].

Third, multiple lines of evidence provide strong support for the involvement of oxidative stress in the development of AD [@bib199]. Mitochondrial dysfunction and increased production of reactive oxygen species are believed to be a contributing factor in the progression of AD. Especially, vitamins C and E are known for their antioxidant properties, both found to be lower in the circulation and the brain in the current meta-analyses. However, also metal ions such as selenium, copper, and zinc have their links to antioxidant capacity through their involvement as cofactor in the endogenous antioxidant enzymes glutathione peroxidase, superoxide dismutase, and catalase [@bib50].

Finally, the anti-inflammatory properties of omega-3 long-chain PUFAs have been recognized for long, as evidenced in many studies. Lipid mediator derivates from omega-3 long-chain PUFAs, such as resolvins, protectins, and maresins, have revealed their potential of being a good alternative in the therapy of several pathophysiological models associated with chronic inflammation (see, for review, Lorente-Cebrian et al. [@bib200]). For example, the neuroprotective and regenerative properties of DHA-derived neuroprotectin D1 bioactivity potently downregulate inflammatory signaling, amyloidogenic APP cleavage and apoptosis [@bib201], and inflammation in peripheral blood mononuclear cells from AD patients [@bib202].

The combined data of this meta-analysis and prior work [@bib15] show that many of the nutrients that play functional roles in phospholipid synthesis, oxidative stress, inflammation, and epigenetic mechanisms are lower in the circulation and the brain of AD patients. This suggests that patients with AD might have a functional deficiency for these nutrients limiting them to counteract the effects of phospholipid loss, elevated oxidative stress, and inflammation and epigenetic modifications.

4.5. Implications {#sec4.5}
-----------------

The previously outlined differences in nutrient status and the metabolic alterations observed in various other reports suggest potential for nutritional intervention in slowing disease progression. Indeed, over the years, several randomized double-blind clinical studies have been performed in patients with AD supplementing omega-3 fatty acids, B-vitamins, or antioxidants. However, recent systematic reviews/meta-analyses show no clear benefits of omega-3 fatty acids (seven eligible studies) [@bib203], vitamin E [@bib204], folic acid alone, or multivitamin B supplements (three eligible studies) [@bib205] in the treatment of AD. In light of the findings of these meta-analyses and the metabolic alterations observed in other studies, it may not be so surprising that interventions with single nutrients are resulting in little beneficial effects. Moreover, it suggests that nutritional intervention in AD should comprise intervention with multiple nutritional components at once to be effective [@bib206].

4.6. Conclusion {#sec4.6}
---------------

The current investigation suggests that patients with AD have impaired availability of DHA, choline, vitamin B~12~, folate, vitamin C, and vitamin E in the brain. These lower levels are in line with the lower circulatory levels observed in this and previous studies [@bib15]. The brain is dependent on nutrient supply from the circulation, which in combination with nutrient involvement in AD-pathophysiological mechanisms suggests that patients with AD may have specific nutritional requirements. This hypothesis could be tested using a multicomponent nutritional intervention as suggested previously. In addition, to further improve our understanding when in the disease spectrum the lower nutrient levels begin to manifest, the field would benefit from studies investigating the temporal relationship between AD-pathophysiology and nutrient status.Research in Context1.Systematic review: Literature was reviewed to evaluate differences in brain and circulatory micronutrient and fatty acid availability between Alzheimer\'s disease (AD) patients and cognitively intact elderly controls. Except for previous work on circulatory vitamin status, to date, no meta-analysis is available that is inclusive for many publications reporting results for brain and/or circulatory nutrient status in AD.2.Interpretation: Significant effects across a range of nutrients provide evidence that brain and circulatory nutrient levels are lower in AD. Provided the postulated roles for these nutrients in AD-pathological processes (e.g., synapse loss and disrupted phospholipid homeostasis), the concept is emerging that these nutrients become conditionally essential for AD patients.3.Future directions: Additional research is needed investigating AD pathophysiology in relation to lower nutrient levels, including furthering understanding of AD-specific changes in eating behavior and nutrient metabolism, to determine when in the disease spectrum the lower levels begin to manifest.

M.C.d.W., E.G., A.C.Y., and J.W.S. are employees of Nutricia Advanced Medical Nutrition, Nutricia Research.

[^1]: Abbreviations: AD, Alzheimer\'s disease; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid.
